http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 May 2024 09:19:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>May 2, 2024</chron></span> /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.</p> <div id="prni_dvprnejpgcb1aleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgcb1aleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p><b>Corporate Highlights from Q1 2024 and To Date</b></p> <ul type="disc"><li>Merit Cudkowicz, M.D., <person>M.Sc</person>., chair of neurology and Director of the Sean M. Healey &amp; <span>AMG Center for ALS</span> at <span value="ACORN:4022105003" idsrc="xmltag.org" >Massachusetts General Hospital</span> presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at the <span value="ACORN:6001201425" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+First+Quarter+2024+Business+Update/23161376.html Thu, 02 May 2024 09:19:00 -0400 0QNO A.06822034 A.31066700 A.40221050 A.60012014 LO3 LO3 LO3 LO3 LO3 LO3 LONN LONN LONNE LONNE LONNZ LZAGF LZAGY NRSN O.00222661 O.20026344 O.20042365 O.22422661 O.29757805 O.31364977 O6Z